Additional Left Atrial Appendage Isolation During Balloon Ablation for Persistent or Long-standing Persistent Atrial Fibrillation

NCT ID: NCT04240366

Last Updated: 2024-08-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

350 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-17

Study Completion Date

2028-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Additional left atrial appendage isolation during balloon ablation for persistent or long-standing persistent atrial fibrillation can reduce atrial fibrillation reoccurrence within 3-12 months compared to balloon-based pulmonary vein isolation only.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The intervention in the LALA-LAND-AF trial is the additional LAAI in patients with catheter ablation for persistent AF and will be performed once as index ablation as outlined above. With exception of the index ablation, all patients will be treated according to the current clinical practice guidelines for AF as stated by the European Society of Cardiology (ESC) 11,18 and an expert consensus statement on catheter and surgical ablation1. Patients may be treated with a specific antiarrhythmic drug (AAD) for a maximum of 3 months following the index ablation. No repeat ablation for AF should be performed within the first 3 months. Thereafter, repeat ablations are permitted for recurrent AF irrespective of group allocation. Ablation strategy at repeat ablation includes PV re-isolation if required in both groups and re-isolation of the LAA in the intervention group. In the control group, LAAI may only be performed in case all PV were isolated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Persistent or Long-standing Persistent Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Balloon-based ablation of atrial fibrillation by pulmonary vein isolation alone

Group Type OTHER

Control intervention

Intervention Type PROCEDURE

patients treated with balloon-based ablation of AF by PVI

Group 2

Balloon-based ablation of atrial fibrillation by pulmonary vein and left atrial appendage isolation

Group Type EXPERIMENTAL

Experimental intervention

Intervention Type PROCEDURE

patients treated with balloon-based ablation of AF by PVI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Control intervention

patients treated with balloon-based ablation of AF by PVI

Intervention Type PROCEDURE

Experimental intervention

patients treated with balloon-based ablation of AF by PVI

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Balloon-based ablation of atrial fibrillation by pulmonary vein isolation alone Experimental: Group 2 Balloon-based ablation of atrial fibrillation by pulmonary vein and left atrial appendage isolation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Persistent or long-standing persistent AF (i.e. continuous AF that was/is sustained \>7 days or \>12 months, respectively)
2. Age ≥18 and ≤80 years
3. Indication for AF ablation as per current guidelines

Exclusion Criteria

1. Missing informed consent
2. LAA diameter \>25mm 10mm distant from circumflex artery assessed by TEE
3. Paroxysmal atrial fibrillation
4. Long-standing persistent atrial fibrillation with a continuous AF duration of \>4 years
5. Previous pulmonary vein isolation or MAZE surgery
6. Previous led atrial appendage closure or surgical excision
7. Left atrial diameter \>60 mm at baseline
8. Left atrial thrombus at baseline
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IHF GmbH - Institut für Herzinfarktforschung

OTHER

Sponsor Role collaborator

University of Luebeck

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Roland Richard Tilz, MD

Head of Electrophysiology Department

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Roland R. Tilz, Prof. Dr.

Role: STUDY_DIRECTOR

Universitätsklinikum Schleswig-Holstein, Universitäres Herzzentrum Lübeck, Klinik für Rhythmologie

Sorin S. Popescu, MD

Role: STUDY_CHAIR

Universitätsklinikum Schleswig-Holstein, Universitäres Herzzentrum Lübeck, Klinik für Rhythmologie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Eppendorf, Hamburg, Germany

Hamburg, City state of Hamburg, Germany

Site Status RECRUITING

Asklepios Klinik Altona

Hamburg, City state of Hamburg, Germany

Site Status RECRUITING

Clinic for Rhythmologiy Luebeck, Schleswig-Holstein Germany

Lübeck, Schleswig-Holstein, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Roland Tilz, Prof. Dr.

Role: CONTACT

+49451500 ext. 44672

Charlotte Eitel, Prof. Dr.

Role: CONTACT

+49451500 ext. 44672

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Andreas Metzner, Prof. Dr.

Role: primary

0049407410 ext. 58320

Christian H. Heeger, Prof. Dr.

Role: primary

004940181881 ext. 1221

Roland Tilz, Prof. Dr.

Role: primary

0049451500 ext. 44511

Charlotte Eitel, Prof. Dr.

Role: backup

0049451500 ext. 44511

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

19-323

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.